Evidence map›Paper›PMID 35958322›Full record

ArticleTranslational lung cancer research2022

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.

Tianqing Chu, Wei Zhang, Bo Zhang, Runbo Zhong, Xueyan Zhang, Aiqin Gu, Chunlei Shi, Huimin Wang, Liwen Xiong, Jun Lu and 15 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03628521 (Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03628521 phase1unknown statusnot on this map

Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study

TypeinterventionalSponsorShanghai Chest HospitalRan2018 to 2020Enrolled80ConditionsLung Cancer, Advanced StageArmsAnlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 3 countries.

Tianqing Chu *Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Wei Zhang *Department of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Bo ZhangDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Runbo ZhongDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Xueyan ZhangDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Aiqin GuDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Chunlei ShiDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Huimin WangDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Liwen XiongDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jun LuDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jianlin QianDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yanwei ZhangDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yu DongDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jiajun TengDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Zhiqiang GaoDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Weimin WangDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yinchen ShenDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Wei NieDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jeong Uk LimDivision of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hiren J MehtaDivision of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Gainesville, FL, USA.
Joel W NealDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Yuqing LouDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Jianlin XuDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Hua ZhongDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Baohui HanDepartment of Respiratory, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Shanghai Chest Hospital · CNStanford University · USUniversity of Florida · USYeouido St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The evidence of combined therapies of multi-target agents in first-line treatment of advanced non-small cell lung cancer (NSCLC) was limited. This study aimed to evaluate the safety and efficacy of anlotinib combined with epidermal growth factor receptor ( Methods: This open-label, three-arm, prospective study (NCT03628521) enrolled untreated locally advanced/metastatic NSCLC patients. Patients with Results: A total of 30, 30, and 22 patients were enrolled in cohorts A, B, and C, respectively. There were 3 patients did not complete the treatment in cohort A. In cohorts A and B, ≥ grade 3 treatment-related adverse events (TRAEs) occurred in 77.3% and 60.0% of patients, respectively. The most common TRAEs were rash (10.0%) and decreased platelet count (30.0%) in cohorts A and B, respectively. The ORRs were 92.9% and 60.0% in cohorts A and B, respectively, and DCRs were 96.4% and 96.7%, respectively. The ORR and incidence of ≥ grade 3 TRAEs of cohort C were, which 72.7% and 54.5%, which had been published previously. Median PFSs [95% confidence interval (CI)] were 21.6 (15.6 to 24.9), 13.0 [10.5 to not estimated (NE)], and 15.6 (12.9 to NE) months in cohorts A, B, and C, respectively. Median OS was 28.1 (95% CI: 21.82 to NE) months in cohort B. The 24-month OS rates in cohorts A and C were 87.1% and 83.9%, respectively. Conclusions: Anlotinib-based combinations with

Indexed as

anlotinibchemotherapyerlotinibNon-small cell lung cancer (NSCLC)sintilimab

Identifiers

PMID35958322
PMCPMC9359953
OpenAlexW4288081542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.